Timing of completion lymphadenectomy after positive sentinel node biopsy in patients with melanoma

被引：4

作者：

Ophuis, C. M. C. Oude ^{[1
]}

van Akkooi, A. C. J. ^{[2
]}

Rutkowski, P. ^{[4
]}

Powell, W. E. M. ^{[5
]}

Robert, C. ^{[6
]}

Testori, A. ^{[8
]}

van Leeuwen, B. L. ^{[3
]}

Siegel, P. ^{[9
]}

Eggermont, A. M. M. ^{[7
]}

Verhoef, C. ^{[1
]}

Grunhagen, D. J. ^{[1
]}

机构：

[1] Erasmus MC Canc Inst, Dept Surg Oncol, Groene Hilledijk 301, NL-3075 EA Rotterdam, Netherlands

[2] Netherlands Canc Inst Antoni van Leeuwenhoek, Dept Surg, Amsterdam, Netherlands

[3] Univ Groningen, Univ Med Ctr Groningen, Dept Surg Oncol, Groningen, Netherlands

[4] Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, Dept Soft Tissue Bone Sarcoma & Melanoma, Warsaw, Poland

[5] St Georges Fdn Univ Hosp, Melanoma Unit, London, England

[6] Canc Inst Gustave Roussy, Dept Dermatol & Allergol, Villejuif, France

[7] Canc Inst Gustave Roussy, Board Directors, Villejuif, France

[8] European Inst Oncol, Div Dermatooncol Surg, Milan, Italy

[9] Charite, Dept Dermatol & Allergol, Berlin, Germany

来源：

BRITISH JOURNAL OF SURGERY | 2017年 / 104卷 / 06期

关键词：

DISSECTION; PROGNOSIS; SURVIVAL; TIME; MULTICENTER; RECURRENCE; UPDATE;

D O I：

10.1002/bjs.10475

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

BackgroundNodal staging with sentinel node biopsy (SNB) and completion lymph node dissection (CLND) provides prognostic information to patients with melanoma and their physicians. It is not known whether the timing of CLND is associated with survival outcome and/or CLND tumour load. This study investigated whether CLND timing is associated with CLND tumour load, disease-free survival (DFS) and/or melanoma-specific survival (MSS). MethodsA retrospective cohort of patients with SNB-positive melanoma from nine European Organisation for Research and Treatment of Cancer (EORTC) Melanoma Group centres undergoing surgery between 1993 and 2009 were examined. Patients were selected based on availability of CLND and follow-up data. The CLND interval was defined as the number of days between diagnosis and CLND. Patient and tumour characteristics were collected. Five-year DFS and MSS rates were calculated. Cox and logistic regression analysis were performed, adjusting for known prognostic/predictive indicators. ResultsA total of 784 patients were included in the study. Their median age was 51 (i.q.r. 40-62) years, and 418 patients (533 per cent) were men. Median Breslow thickness was 30 (i.q.r. 20-50)mm, and 148 patients (189 per cent) had a residual tumour load. Median CLND interval was 84 (i.q.r. 65-105) days. Five-year DFS and MSS rates were not significantly different for patients operated on with a median CLND interval of less than 84days and those with an interval of at least 84days (DFS: 542 versus 533 per cent respectively; MSS: 669 versus 651 per cent). In a multivariable Cox model, CLND interval was not a significant prognostic indicator. CLND interval was negatively correlated with identification of positive non-sentinel nodes, but following adjustment for known risk factors this effect was no longer found. ConclusionThe time interval between diagnosis of melanoma and CLND did not influence CLND tumour load, DFS or MSS. No rush

引用

页码：726 / 733

页数：8

共 50 条

[1] Completion lymphadenectomy for melanoma patients with a positive sentinel node biopsy remains standard of care
Henderson, Michael A.
[J]. ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (06) : 761 - 763
[2] Completion Lymphadenectomy for Melanoma Patients With a Positive Sentinel Node Biopsy Remains Standard of Care
Michael A. Henderson
[J]. Annals of Surgical Oncology, 2006, 13 : 761 - 763
[3] Completion Lymphadenectomy for a Positive Sentinel Node Biopsy in Melanoma Patients is Not Associated with a Survival Benefit
Klemen, N. D.
Han, G.
Leong, S. P. L.
Kashani-Sabet, M.
Vetto, J. T.
White, R. L.
Schneebaum, S.
Pockaj, B. A.
Mozzillo, N.
Charney, K. J.
Hoekstra, H.
Sondak, V. K.
Messina, J. L.
Zager, J. S.
Han, D.
[J]. ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : S173 - S173
[4] Completion lymphadenectomy for a positive sentinel node biopsy in melanoma patients is not associated with a survival benefit
Klemen, Nicholas D.
Han, Gang
Leong, Stanley P.
Kashani-Sabet, Mohammed
Vetto, John
White, Richard
Schneebaum, Schlomo
Pockaj, Barbara
Mozzillo, Nicola
Charney, Kim
Hoekstra, Harald
Sondak, Vernon K.
Messina, Jane L.
Zager, Jonathan S.
Han, Dale
[J]. JOURNAL OF SURGICAL ONCOLOGY, 2019, 119 (08) : 1053 - 1059
[5] Is completion lymphadenectomy after a positive sentinel lymph node biopsy for cutaneous melanoma always necessary?
Elias, N
Tanabe, KK
Sober, AJ
Gadd, MA
Mihm, MC
Goodspeed, B
Cosimi, AB
[J]. ARCHIVES OF SURGERY, 2004, 139 (04) : 400 - 404
[6] Is completion lymphadenectomy after a positive sentinel lymph node biopsy for cutaneous melanoma always necessary? Discussion
Cady, B
Elias
Osteen, R
Wanebo, H
Colacchio, T
[J]. ARCHIVES OF SURGERY, 2004, 139 (04) : 404 - 405
[7] Optimal extent of completion lymphadenectomy for patients with melanoma and a positive sentinel node in the groin
Verver, D.
Madu, M. F.
Ophuis, C. M. C. Oude
Faut, M.
de Wilt, J. H. W.
Bonenkamp, J. J.
Grunhagen, D. J.
van Akkooi, A. C. J.
Verhoef, C.
van Leeuwen, B. L.
[J]. BRITISH JOURNAL OF SURGERY, 2018, 105 (01) : 96 - 105
[8] Complication rates of completion lymphadenectomy following positive sentinel lymph node biopsy versus therapeutic lymphadenectomy in melanoma
Smith, J. R. O.
Wilson, A.
Stone, C.
[J]. JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY, 2016, 69 (07): : 1011 - 1012
[9] Adjuvant Therapy is Effective for Melanoma Patients with a Positive Sentinel Lymph Node Biopsy Who Forego Completion Lymphadenectomy
Norma E. Farrow
Vignesh Raman
Taylor P. Williams
Kayla Y. Nguyen
Douglas S. Tyler
Georgia M. Beasley
[J]. Annals of Surgical Oncology, 2020, 27 : 5121 - 5125
[10] Adjuvant Therapy is Effective for Melanoma Patients with a Positive Sentinel Lymph Node Biopsy Who Forego Completion Lymphadenectomy
Farrow, Norma E.
Raman, Vignesh
Williams, Taylor P.
Nguyen, Kayla Y.
Tyler, Douglas S.
Beasley, Georgia M.
[J]. ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (13) : 5121 - 5125

← 1 2 3 4 5 →